logo
Book a meeting
GO Therapeutics

Go Therapeutics

Biotechnology, 22 Strathmore, Natick, Massachusetts, 01760, United States, 1-10 Employees

gotherapeutics.com

  • LinkedIn

Who is GO THERAPEUTICS

GO Therapeutics is exploiting unique aspects of cancer cell biology to develop a new class of cancer therapies for previously intractable solid tumors. We target O-linked glycoproteins sp...

Read More

lock icon Get Full Access
map
  • 22 Strathmore, Natick, Massachusetts, 01760, United States Headquarters: 22 Strathmore, Natick, Massachusetts, 01760, United States
  • 2014 Date Founded: 2014
  • 1-10 Employees: 1-10
  • dollar-icon Revenue: Under $1 Million
  • tech-icon Active Tech Stack: See technologies

industries-icon Industry: Biotechnology

SIC SIC Code: 6159 | NAICS Code: 522293 | Show More

checked-icon Does something look wrong? Fix it. | View contact records from GO THERAPEUTICS

GO Therapeutics Org Chart and Mapping

Employees
Aaron Groen

Aaron Groen

Senior Director

See Full Org Chart arrow
email-formate-icon
View Email Formats for GO Therapeutics
arrow
signout-image
You are signed out

Sign in to CIENCE GO Data to uncover contact details

Join Now

crown-icon Free credits every month

Frequently Asked Questions Regarding GO Therapeutics

Answer: GO Therapeutics's headquarters are located at 22 Strathmore, Natick, Massachusetts, 01760, United States

Answer: GO Therapeutics's official website is https://gotherapeutics.com

Answer: GO Therapeutics's revenue is Under $1 Million

Answer: GO Therapeutics's SIC: 6159

Answer: GO Therapeutics's NAICS: 522293

Answer: GO Therapeutics has 1-10 employees

Answer: GO Therapeutics is in Biotechnology

Answer: GO Therapeutics contact info: Phone number: Website: https://gotherapeutics.com

Answer: GO Therapeutics is exploiting unique aspects of cancer cell biology to develop a new class of cancer therapies for previously intractable solid tumors. We target O-linked glycoproteins specific to cancer cells to develop proprietary, high-affinity antibodies to novel cancer-specific targets. Our antibodies are the basis for a broad array of potent cancer-killing modalities including T-cell bispecifics (TCBs), CAR-T, and antibody drug conjugates (ADCs). Each are designed to kill cancer while sparing healthy tissue.

Answer:

Premium Sales Data for Prospecting

  • Sales data across over 200M records

  • Up-to-date records (less decayed data)

  • Accurate Email Lists (real-world tested)

  • Powerful search engine and intuitive interface

lock icon Get Full Access